115 related articles for article (PubMed ID: 27805003)
1. Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer.
Mezheyeuski A; Hrynchyk I; Karlberg M; Portyanko A; Egevad L; Ragnhammar P; Edler D; Glimelius B; Östman A
Sci Rep; 2016 Nov; 6():36149. PubMed ID: 27805003
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
3. A stroma-related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer.
Zhou R; Sun H; Zheng S; Zhang J; Zeng D; Wu J; Huang Z; Rong X; Bin J; Liao Y; Shi M; Liao W
J Cell Mol Med; 2020 Mar; 24(5):3229-3241. PubMed ID: 31989761
[TBL] [Abstract][Full Text] [Related]
4. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
[TBL] [Abstract][Full Text] [Related]
5. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
6. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
8. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
[TBL] [Abstract][Full Text] [Related]
9. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
10. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
[TBL] [Abstract][Full Text] [Related]
12. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
15. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
17. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
18. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
[TBL] [Abstract][Full Text] [Related]
19. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
